Compare TOUR & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | ACRS |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 314.2M |
| IPO Year | 2014 | 2015 |
| Metric | TOUR | ACRS |
|---|---|---|
| Price | $0.72 | $2.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 225.1K | ★ 1.2M |
| Earning Date | 12-05-2025 | 02-26-2026 |
| Dividend Yield | ★ 5.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $78,261,883.00 | $15,742,000.00 |
| Revenue This Year | $12.27 | N/A |
| Revenue Next Year | $10.18 | N/A |
| P/E Ratio | $107.12 | ★ N/A |
| Revenue Growth | ★ 9.07 | N/A |
| 52 Week Low | $0.62 | $1.05 |
| 52 Week High | $1.17 | $3.48 |
| Indicator | TOUR | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 42.35 |
| Support Level | $0.62 | $2.49 |
| Resistance Level | $0.74 | $3.04 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 71.86 | 24.68 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.